Reply to: Technical challenges of studying the impact of plasma components on the efficacy of lipid nanoparticles for vaccine and therapeutic applications.

Liu, Kai; Lázaro-Ibáñez, Elisa; Lerche, Michael; Lindén, Daniel; Salvati, Anna; Sabirsh, Alan

Liu, Kai; Lázaro-Ibáñez, Elisa; Lerche, Michael; Lindén, Daniel; Salvati, Anna; Sabirsh, Alan.

Affiliation

Liu K; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Lázaro-Ibáñez E; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Lerche M; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Lindén D; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Salvati A; Division of Endocrinology, Department of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Sabirsh A; Department of Nanomedicine & Drug Targeting, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, 9713AV, The Netherlands.

Nat Commun ; 15(1): 3853, 2024 May 09.

Article de En | MEDLINE | ID: mdl-38724506

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Nanoparticules / Lipides Limites: Animals / Humans Langue: En Journal: Nat Commun / Nature communications Sujet du journal: BIOLOGIA / CIENCIA Année: 2024 Type de document: Article Pays d'affiliation: Suède Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google